Skip to main content

Biosimilars

Adoption of Biosimilars—Why the Delay?

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Meeting Highlights

Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice

Comparing Single-Center Outcomes Between Reference and Biosimilar Granulocyte Colony-Stimulating Factor Drugs Used for Autologous Stem-Cell Mobilization

Trace Bartels, PharmD; Molly Klanderman, PhD, MS; Jaime Rogers, MSN, RN; Kristin Gray, MSN, RN; Heidi Kosiorek, MS; Chris Coughlin, PharmD, BCOP

Meeting Highlights

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

Comparative Efficacy and Safety of the Bevacizumab Biosimilar MIL60 versus Bevacizumab Reference in Patients with Advanced or Recurrent Nonsquamous NSCLC

Same-Day Pegfilgrastim or PFG-cbqv Prophylaxis of Chemotherapy-Induced Neutropenia in Bendamustine plus Rituximab and CHOP±R Regimens in Patients with Lymphoma and CLL

Same-Day Pegfilgrastim or Pegfilgrastim-cbqv Prophylaxis in miniCHOP Chemotherapy-Based Regimens for Non-Hodgkin Lymphoma

Demographics and Clinical Characteristics of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-awwb in Real-World Oncology Clinics

Impact of the Oncology Care Model on Use of Bone Supportive Medications, Antiemetics, and Growth Factors

Cost-Efficiency Analysis of Conversion from Pegfilgrastim with On-Body Injector to Pegfilgrastim-jmdb to Provide Budget-Neutral Expanded Access to Prophylaxis and Treatment

1
2
3
4

Page 1 of 7
Results 1 - 10 of 65